Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors (Q39252597)

10 September 2017

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors (English)

1 reference

10 September 2017

Sven Rottenberg

19

0 references

author name string

Janneke E Jaspers

1

1 reference

10 September 2017

Ariena Kersbergen

2

1 reference

10 September 2017

Ute Boon

3

1 reference

10 September 2017

Wendy Sol

4

1 reference

10 September 2017

Liesbeth van Deemter

5

1 reference

10 September 2017

Serge A Zander

6

1 reference

10 September 2017

Rinske Drost

7

1 reference

10 September 2017

Ellen Wientjens

8

1 reference

10 September 2017

Jiuping Ji

9

1 reference

10 September 2017

Amal Aly

10

1 reference

10 September 2017

James H Doroshow

11

1 reference

10 September 2017

Aaron Cranston

12

1 reference

10 September 2017

Niall M B Martin

13

1 reference

10 September 2017

Alan Lau

14

1 reference

10 September 2017

Mark J O'Connor

15

1 reference

10 September 2017

Shridar Ganesan

16

1 reference

10 September 2017

Piet Borst

17

1 reference

10 September 2017

Jos Jonkers

18

1 reference

10 September 2017

25 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

3

1 reference

10 September 2017

68-81

1 reference

10 September 2017

1

1 reference

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

10 September 2017

1 reference

12 December 2020

Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

1 reference

12 December 2020

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

1 reference

12 December 2020

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

1 reference

12 December 2020

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

1 reference

12 December 2020

BRCA1-independent ubiquitination of FANCD2

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

12 December 2020

A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.

1 reference

12 December 2020

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

1 reference

12 December 2020

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

12 December 2020

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

1 reference

12 December 2020

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

1 reference

12 December 2020

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair

1 reference

12 December 2020

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

1 reference

12 December 2020

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase

1 reference

12 December 2020

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

1 reference

12 December 2020

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle.

1 reference

12 December 2020

Tumour evolution inferred by single-cell sequencing

1 reference

12 December 2020

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

12 December 2020

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

1 reference

12 December 2020

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

12 December 2020

CDK targets Sae2 to control DNA-end resection and homologous recombination

1 reference

12 December 2020

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

1 reference

12 December 2020

Human CtIP mediates cell cycle control of DNA end resection and double strand break repair

1 reference

12 December 2020

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

12 December 2020

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

1 reference

12 December 2020

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

1 reference

12 December 2020

10.1158/2159-8290.CD-12-0049

Identifiers

DOI

1 reference

10 September 2017

1 reference